Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: Implications for decision making

PharmacoEconomics

Volumn 24, Issue 6, 2006, Pages 523-535

  Boersma, Cornelis ^a,d   Atthobari, Jarir ^a   Gansevoort, Ron T ^a   De Jong Van Den Berg, Lolkje T W ^a   De Jong, Paul E ^a   De Zeeuw, Dick ^a   Annemans, Lieven J P ^b,c   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY   (Belgium)

^c IQVIA   (United States)

^d NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; VALSARTAN;

CLINICAL TRIAL; DIABETIC PATIENT; DRUG EFFICACY; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CLINICAL TRIALS; DECISION MAKING, ORGANIZATIONAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; EUROPE; HUMANS; UNITED STATES;

EID: 33745104728     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624060-00001     Document Type: Review

References (68)

1. Laverman GD, Remuzzi G, Ruggenenti P. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol 2004; 15: S64-70
2. Postma MJ, Kruidhof H, de Jong-van den Berg LT, et al. Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with type 2 diabetes. Expert Opin Pharmacother 2003; 4 (9): 1543-50
3. Coyle JD, Gardner SF, White CM. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus. Ann Pharmacother 2004; 38: 1731-8
4. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60
6. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12): 870-8
7. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28 Suppl. 1: S4-36
8. Rippin JD, Barnett AH, Bain SC. Cost-effective strategies in the prevention of diabetic nephropathy. Pharmacoeconomics 2004; 22 (1): 9-28
9. van Hout B, Simeon GP, McDonnell J, et al. Economic evaluation of benazepril in chronic renal insufficiency. Kidney Int 1997; 52 (63): S159-62
10. van Ballegooie E, van Everdingen JJE. CBO guidelines on diagnosis, treatment, and prevention of complication in diabetes mellitus, retinopathy, foot ulcers, nephropathy and cardiovascular diseases: Dutch Institute for Quality Assurance [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2000; 144 (9): 413-8
11. van Os N, Niessen LW, Bilo HJ, et al. Diabetes nephropathy in the Netherlands: a cost-effectiveness analysis of national clinical guidelines. Health Policy 2000; 51: 135-47
12. Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant 2003; 18: 2059-66
13. USRDS annual data report 2004. Bethesda (MD): National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, 2004
14. Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82
15. Diercks GFH, Hillege HL, van Boven AJ, et al. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol 2002; 40 (8): 1401-7
16. Asselbergs FW, Hillege HL, van Gilst WH. Framingham score and microalbuminuria: combined future targets for primary prevention? Kidney Int 2004; 66 Suppl. 92: S111-4
17. Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther 2003; 25 (12): 3044-64
18. Zanella MT, Ribiero AB. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. Clin Ther 2002; 24 (7): 1019-34
19. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003; 26: 683-7
20. Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive type 2 diabetic nephropathy. Clin Ther 2003; 25 (7): 2102-19
21. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003
22. Gerstein HC, Yusuf S, Mann JFE, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9
23. Yusuf S, Sleight P, Dagenais G, et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342 (3): 145-53
24. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-7
25. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-20
26. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329 (20): 1456-62
27. Huston P, Peterson R. Withholding proven treatment in clinical research. N Engl J Med 2001; 345: 912-4
28. Data on file, Merck & Co., Inc. 2003
29. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62 (8): 1253-87
30. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 (8): 1345-53
31. Ruilope L, Jäger B. Eprosartan for the treatment of hypertension. Expert Opin Pharmacother 2003; 4: 107-14
32. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: the MicroAlbuminuria Reduction With VALsartan (MARVAL) study investigators. Circulation 2002; 106: 672-8
33. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10
34. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Lancet 2003; 362: 782-8
35. Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6
36. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351 (19): 1941-51
37. Gomma AH, Fox KM. The EUROPA trial: design, baseline demography and status of the substudies. The EUROPA investigators. Cardiovasc Drugs Ther 2001; 15: 169-79
38. Ferrari R, Arbustini E, Blann A, et al. PERTINENT (PER-indopril- Thrombosis, InflammatioN, Endothelial dysfunction and Neurohormonal activation Trial): a sub-study of the EUROPA Study. Cardiovasc Drugs Ther 2003; 17: 83-91
39. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002; 23: 377-401
40. Briggs A, Sculpher M. An introduction to markov modelling for economic evaluation. Pharmacoeconomics 1998; 13 (4): 397-409
41. International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Pharmacoeconomic guidelines around the world [online]. Available from URL: http://www.ispor.org/PEguidelines/index.asp [Accessed 2005 Jun 30]
42. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32
43. Postma MJ, Bartstra J, Annemans LJP. Angiotensin-II antagonists in diabetes mellitus type 2 [in Dutch]. Pharm Weekbl 2004; 139 (33): 1060-3
44. Palmer AJ, Annemans L, Roze S, et al. Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension [in German]. Dtsch Med Wochenschr 2004; 129: 13-8
45. Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004; 18 (10): 733-8
46. Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27: 1897-903
47. Palmer AJ, Annemans L, Roze S, et al. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney Int 2005; 67 Suppl. 93: S52-54
48. Gold MR, Siegel JE, Russel LB, et al., editors. Cost-effectiveness in health and medicine. New York: University Press, 1996
49. Alexander CM, Lyle PA, Keane WF, et al. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66 Suppl. 92: S115-7
50. Gerth WC, Remuzzi G, Viberti G, et al. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney Int 2002; 62 (82): S68-72
51. College voor zorgverzekeringen (CvZ). Guidelines for pharmacoeconomic research [in Dutch]. Amstelveen: College voor zorgverzekeringen, 1999
52. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999; 131 (9): 660-7
53. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM: I. Model construction and assumptions. Diabetes Care 1997; 20 (5): 725-34
54. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20 (5): 735-44
55. Palmer AJ, Roze S, Valentine WJ, et al. Irbesartan is projected to be cost and life saving compared to standard blood pressure control alone for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria in Spanish, Swedish and Swiss settings [abstract]. Value Health 2004; 7 (6): 655
56. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351 (91): 1952-61
57. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-81
58. Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Ann Intern Med 1998; 128: 982-8
59. Lindholm LH, Dahlöf B, Edelman JM, et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362: 619-20
60. Schädlich PK, Brecht JG, Rangoonwala B, et al. Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective. Pharmacoeconomics 2004; 22 (15): 955-73
61. Björholt I, Andersson FL, Kahan T, et al. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study. J Intern Med 2002; 251: 508-17
62. Strippoli GFM, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828-31
63. Pylypchuk GB. ACE-inhibitor versus angiotensin II blocker induced cough and angioedema. Ann Pharmacother 1998; 32: 1060-6
64. Fuchs SA, Meyboom RHB, van Puijenbroek EP, et al. Use of angiotensin receptor antagonists in patients with ACE-inhibitor induced angiodema. Pharm World Sci 2004; 26: 191-2
65. Mitch WE. Treating diabetic nephropathy: are there only economic issues? N Engl J Med 2004; 351 (19): 1934-6
66. Palmer AJ, Rodby RA. Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. Kidney Int 2004; 66 Suppl. 92: S118-120
67. Atthobari J, Asselbergs FW, Boersma C, et al. Cost-effectivetients. ness of screening for albuminuria and subsequent treatment with ACE-inhibitor to prevent cardiovascular events: a pharmacoeconomic analysis linked to the PREVEND and PREVEND-IT studies. The PREVEND-IT study group. Clin Ther 2006; 28 (3): 432-44
68. Johannesson M, Jönsson B, Kjekhus J, et al. Cost-effectiveness of simvastatin treatment in lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-6